- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03189758
Dietary Sodium (DS) Intervention to Reduce Volume Overload and Tissue Sodium in Magnetic Resonance Imaging (MRI) for Hemodialysis (HD) Patients (DSMRI)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Recent studies illustrate that tissue sodium is regulated by immune cells in interstitial fluids such as the skin and muscle. Localized immune responses in these tissues can promote vascular endothelial growth factor secretion to promote lymphatic release of fluid and electrolytes, which has significant implications for blood pressure control and cardiovascular health. Furthermore, sodium composition of the diet has the potential to promote beneficial gut bacteria in addition to lowering auto-immune response and blood pressure.
The purpose of this pilot study is to utilize this 21Na-MRI coil to quantify changes of sodium levels in the skin and skeletal muscle in hemodialysis treatments before and after a low-sodium diet intervention. In this study, all HD patients will undergo a 30-day observation period (CON) followed by a low-sodium diet period (INT) for 30 additional days. Testing will occur at baseline and after each time-point (three time points total). During the CON period, patients will have no changes to their normal dialysis treatment, and will be asked to follow their normal diet. During the INT period, patients will provided a low- sodium diet intervention that includes receiving 3 low sodium meals per day and snacks provided by momsmeals.com.
The study outcomes include: clinical outcomes (hospitalizations, treatment efficiency) changes in tissue sodium, cardiovascular measures (blood pressure, cardiac output, and vascular resistance) and fluid/hydration status (total body water, extracellular fluid) using bioelectrical impedance. We will also collect serum to analyze the relationship between changes in tissue sodium and serum minerals (e.g. sodium and potassium), and other factors believed to help regulate tissue sodium levels, including vascular endothelial growth factor (VEGF), and markers of inflammation (CRP, IL-6). Additionally, we plan to collect patient stool samples to analyze how changes in dietary sodium consumption impact the gut microbiome.
This study will demonstrate the feasibility of utilizing 23Na-MRI to quantify skin and muscle sodium levels, as well as provide pilot data regarding the relationship between tissue sodium accumulation, inflammation, the gut microbiome, insulin resistance, and cardiovascular health in hemodialysis patients. Results from this study will then be used to design larger trials to investigate related questions.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Luis M Perez, BS
- Phone Number: 7192444805
- Email: lmperez2@illinois.edu
Study Contact Backup
- Name: Ken Wilund, PhD
- Phone Number: 2172656755
- Email: kwilund@illinois.edu
Study Locations
-
-
Illinois
-
Urbana, Illinois, United States, 61801
- Recruiting
- University of Illinois at Urbana-Champaign
-
Contact:
- Ken Wilund, PhD
- Phone Number: 217-265-6755
- Email: kwilund@illinois.edu
-
Principal Investigator:
- Ken Wilund, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Willingness to sign informed consent document and age 18 or greater.
- Willingness to consume intervention meals 3 times per day (with provided snacks) for 30 days.
Exclusion Criteria:
- Individuals with pacemakers (exclusion from cardiovascular testing only)
- Individuals with major amputations (i.e. whole limb: foot, ankle, leg, arm)
- Individuals with ferric metal implants or devices in the body (excluded from MRI testing only)
- Claustrophobic individuals (excluded from MRI testing only)
- Individuals that do not otherwise meet MRI screening requirements (mentioned below, excluded from MRI testing only)
- Individuals on HD therapy <3 days per week or <3 months
- Currently following a sodium restricted diet approximately <1,500 mg per day (only excluded from MRI analysis)
- Currently diagnosed GI disorder or disease or infection
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Interventional Model: SEQUENTIAL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Intervention
Participants will follow a Observational Control Diet (CON) diet followed by an Controlled Dietary Sodium Restriction (INT) diet.
|
Participants will follow their usual or normal diet for 30 days (days 1-30) while under study observation.
Other Names:
Participants will be provided with all meals and snacks daily, for 30 days (days 31-60).
These meals should meet KDQOI guidelines for energy and protein (30-35 kcal/kg & 1.2 g/kg) as well as low phosphorus, potassium, and sodium.
The meals are formulated to less than 600-800 mg sodium each (<2,000g/day) and will be ordered and delivered through momsmeals.com
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Interdialytic weight gain
Time Frame: 28 days
|
Interdialytic weight from clinic records
|
28 days
|
Tissue sodium
Time Frame: 28 days
|
MRI detected sodium content in the lower leg (mM)
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hydration status
Time Frame: 28 days
|
Bio-impedance measured total body water, extracellular fluid, intracellular fluid, and calculated fluid volume overload
|
28 days
|
Cardiovascular function
Time Frame: 28 days
|
Standard blood pressure
|
28 days
|
Biochemical markers
Time Frame: 28 days
|
Vascular endothelial growth factor-C (VEGF-C), C-reactive protein (CRP), interleukin (IL-6), tumour necrosis factor alpha (TNF-a), endothelial nitric oxide (eNOS), serum sodium (Na)
|
28 days
|
Gut microbiome (stool sample)
Time Frame: 28 days
|
DNA sequencing, bacteria phyla and taxa, stool consistency, gastrointestinal symptoms
|
28 days
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 17530
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Failure, Chronic
-
Centre Hospitalier Universitaire DijonTerminatedEnd-stage Chronic Kidney FailureFrance
-
Baxter Healthcare CorporationRecruitingAcute Kidney Failure | Chronic Kidney FailureChina
-
Texas A&M UniversityWithdrawnChronic Kidney FailureUnited States
-
Angiodynamics, Inc.TerminatedChronic Kidney Disease | Acute Kidney Injury | Acute Renal Failure | Renal Failure Chronic Contrast InducedUnited States
-
Hopital Jean MinjozUnknownCardiac Surgical Procedures | Preoperative KIDNEY FAILURE, CHRONIC | Postoperative KIDNEY FAILURE, ACUTEFrance
-
University of WashingtonJohns Hopkins University; National Institute of Diabetes and Digestive and... and other collaboratorsRecruitingChronic Kidney Diseases | Acute Renal Failure | Acute Renal Injury | Acute Kidney Failure | Chronic Renal Insufficiency | Kidney Failure, Acute | Renal Insufficiency, Acute | Acute Renal Insufficiency | Acute Kidney Insufficiency | Renal Failure, Acute | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney... and other conditionsUnited States
-
Pharmagest InteractiveCompletedChronic Kidney DiseasesFrance
-
Nantes University HospitalNot yet recruiting
-
Ozge AKBABAAtaturk UniversityCompletedChronic Kidney FailureTurkey
-
Chinese PLA General HospitalCompletedKidney Failure,ChronicChina
Clinical Trials on Observational Control Diet
-
University of MinnesotaAgency for Healthcare Research and Quality (AHRQ)RecruitingTraumatic Brain Injury | Venous ThromboembolismUnited States
-
Fresenius KabiCompletedChronic Kidney DiseaseChina
-
Fresenius KabiCompletedChronic Kidney DiseaseHungary
-
Fresenius KabiCompletedChronic Kidney DiseaseRussian Federation
-
University of GeorgiaCompletedInflammation | ObesityUnited States
-
Fazer GroupNokia Technologies Oy; Nightingale Health Oy; Tekes - the Finnish Funding Agency... and other collaboratorsCompletedCognitive Performance | Physiological Stress | LDL CholesterolFinland
-
Purdue UniversityAlliance for Potato Research and EducationUnknownHypertensive DiseaseUnited States
-
Lund UniversityLund University HospitalCompletedObesity | Diet Modification | Cardiovascular Risk FactorSweden
-
Universidade Federal do Rio de JaneiroCompletedType 1 Diabetes MellitusBrazil
-
Isfahan University of Medical SciencesCompleted